ASO Author Reflections: Beyond the Binary: Using IHC Status to Predict Response to Neoadjuvant Therapy in HER2+ Early-Stage Breast Cancer

被引：0
|
作者：
Leah K. Winer [1 ]
Austin D. Williams [2 ]
机构：
[1] University of Kentucky,Division of Surgical Oncology, Department of Surgery
[2] Fox Chase Cancer Center,Division of Breast Surgery, Department of Surgical Oncology
来源：
Annals of Surgical Oncology | 2025年 / 32卷 / 2期
关键词：
D O I：
10.1245/s10434-024-16606-w
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：967 / 968
页数：1
相关论文
共 50 条
  • [21] Predictive score for response to neoadjuvant chemotherapy in early-stage HR + /HER2-breast cancer
    Coelho, Joao Queiros
    Lau, Beatriz
    Pichel, Rita
    Guerra, Laura
    Miranda, Hugo
    Romao, Raquel
    Sousa, Maria Joao
    Goncalves, Fernando
    Simoes, Joana
    Azevedo, Sergio Xavier
    Araujo, Antonio
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025,
  • [22] Prediction of response to neoadjuvant therapy in early-stage breast cancer using a biophysical simulation platform
    Cole, J.
    Braun, E.
    Carrigan, P.
    Antony, A.
    Pfeiffer, J.
    Peterson, J.
    Team, T. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S172 - S172
  • [23] ASO Author Reflections: Early-Stage Lobular Breast Cancer: Axillary Treatment in the Z0011 Era
    Mamtani, Anita
    Morrow, Monica
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (Suppl 3) : S715 - S716
  • [24] ASO Author Reflections: Early-Stage Lobular Breast Cancer: Axillary Treatment in the Z0011 Era
    Anita Mamtani
    Monica Morrow
    Annals of Surgical Oncology, 2019, 26 : 715 - 716
  • [25] Personalized circulating tumor DNA monitoring to predict response to neoadjuvant therapy in patients with early-stage breast cancer
    George, Mridula
    Meghal, Trishala
    Omene, Coral
    Kalashnikova, Ekaterina
    Fielder, Janie
    Ohri, Nisha
    Kumar, Shicha
    Burkovskaya, Valeria
    Patel, Preena
    Young, Ashley
    Racenstein, Melanie
    Bauman, Tinamarie
    Mchayleh, Wassim
    Toppmeyer, Deborah
    Ganesan, Shridar
    Rosen, Barry
    Rodriguez, Angel
    Liu, Minetta
    CANCER RESEARCH, 2024, 84 (09)
  • [26] Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer?
    Maltoni, Roberta
    Palleschi, Michela
    Altini, Mattia
    Massa, Ilaria
    Balzi, William
    Ravaioli, Sara
    Tumedei, Maria Maddalena
    Rocca, Andrea
    Bravaccini, Sara
    CLINICAL BREAST CANCER, 2020, 20 (04) : 359 - 360
  • [27] Pathological Response to Herceptincontaining Neoadjuvant Therapy in HER2 IHC2+/ ISH+ and IHC3+Early-Stage Breast Cancers
    Zhan, Haiying
    Chan, Nay Nwe Nyein
    Rimm, David
    LABORATORY INVESTIGATION, 2025, 105 (03)
  • [28] ASO Author Reflections: Improved Survival for Stage IV Breast Cancer: Considerations for Surgery in the Era of HER2-Targeted Therapy
    Mudgway, Ross
    Lum, Sharon S.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (08) : 2721 - 2722
  • [29] ASO Author Reflections: Improved Survival for Stage IV Breast Cancer: Considerations for Surgery in the Era of HER2-Targeted Therapy
    Ross Mudgway
    Sharon S. Lum
    Annals of Surgical Oncology, 2020, 27 : 2721 - 2722
  • [30] Systemic therapy for HER2-positive early-stage breast cancer
    Mathew, Aju
    Romond, Edward H.
    CURRENT PROBLEMS IN CANCER, 2016, 40 (2-4) : 106 - 116
12345